arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Annovis Bio, Inc.

ANVS
$1.26 ▲ +0.07 (+6.33%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
31 Visible periods
20 Metrics
Peer-ranked Benchmarks
Price Chart
20
Health
Poor
Bearish
auto_awesome

Analytical Summary

Annovis Bio, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $47.3M
Dividend Yield
Revenue Growth
Op. Margin
ROIC 267.0%
FCF / Share $-0.58
Trailing P/E
Price / Book
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Sep 22, 2026.

31-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$0.00
Net Income Profit after all expenses
$-17.61M
↓ -218.0%
FCF / Share Free cash flow per share
$-0.58
↓ -80.5%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns
4
Cash Quality
60

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 8 years · 31 quarters